Integra LifeSciences (NASDAQ:IART) PT Lowered to $20.00 at BTIG Research

Integra LifeSciences (NASDAQ:IART) had its price target trimmed by BTIG Research from $22.00 to $20.00 in a report released on Wednesday, Benzinga reports. The firm currently has a sell rating on the life sciences company’s stock.

Other equities analysts have also issued reports about the stock. Oppenheimer lowered shares of Integra LifeSciences from an outperform rating to a market perform rating in a research report on Tuesday, May 7th. JMP Securities cut their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a market outperform rating for the company in a report on Tuesday, July 30th. StockNews.com lowered Integra LifeSciences from a buy rating to a hold rating in a report on Monday, May 13th. Wells Fargo & Company downgraded Integra LifeSciences from an overweight rating to an equal weight rating and cut their target price for the stock from $45.00 to $25.00 in a research note on Tuesday, May 7th. Finally, Bank of America decreased their price target on Integra LifeSciences from $42.00 to $26.00 and set an underperform rating on the stock in a research note on Tuesday, May 7th. Four research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average target price of $28.63.

Integra LifeSciences Stock Down 1.8 %

Integra LifeSciences stock opened at $20.34 on Wednesday. The stock has a 50-day simple moving average of $26.00 and a 200-day simple moving average of $30.44. The company has a market capitalization of $1.60 billion, a P/E ratio of 40.68, a PEG ratio of 0.84 and a beta of 1.11. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 3.39. Integra LifeSciences has a fifty-two week low of $20.10 and a fifty-two week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same period last year, the firm posted $0.71 earnings per share. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. Equities research analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

Several large investors have recently bought and sold shares of IART. Signaturefd LLC boosted its position in shares of Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after buying an additional 415 shares in the last quarter. Handelsbanken Fonder AB grew its position in shares of Integra LifeSciences by 32.3% in the fourth quarter. Handelsbanken Fonder AB now owns 12,302 shares of the life sciences company’s stock valued at $536,000 after purchasing an additional 3,000 shares during the last quarter. Hexagon Capital Partners LLC increased its stake in shares of Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 370 shares in the last quarter. Natixis Advisors L.P. acquired a new position in shares of Integra LifeSciences during the 4th quarter worth approximately $458,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Integra LifeSciences by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 563,601 shares of the life sciences company’s stock valued at $24,545,000 after buying an additional 17,863 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.